Fake News in Marijuana Business Daily on Khiron (TSXV: KHRN)

An article by Alfredo Pascual in Marijuana Business Daily dated May 31, 2019 had the effect of creating, in my opinion, a completely false impression about Khiron Life Sciences (TSXV: KHRN) (OTCQB: KHRNF) and its position with Colombian regulations.

As a person who has spent an entire career reading and writing financial reports on companies, financial markets and financial variables, I believe I have the skills necessary to identify an unacceptably researched investment report when I see it. Having a Bachelor of Commerce, Masters of Business Administration and a Chartered Financial Analyst degree as well has having been licensed as an Investment Advisor and Portfolio Manager, I believe I have the credentials and expertise to say Mr. Pascual’s article in Marijuana Business Daily would not pass muster as a professionally written research report. Not even close.

But never mind this misleading article, consider the facts released by KHRN recently:

• The construction and the initiation of operations in its cultivation, extraction, and analysis facilities in Ibague, Colombia have been completed.

• Significant progress has been made towards the commercial registration and production of medical cannabis products targeting 6 million potential patients across the country.

• Owns and operates one of the most sophisticated medical cannabis cultivation and processing facilities in Latin America.

• Completed development of a state-of-the-art, 14,000 sq. ft. GMP and ISO 17025 compliant extraction and analysis lab.

• Obtained approval from the National Cultivar Registry and Colombian Institute of Agriculture (ICA) to list a proprietary selection of strains forming a targeted portfolio to address the major conditions of pain, epilepsy and sleep disorders.

• This approval positions KHRN to initiate commercial registration, production and sale of its medical cannabis products across Colombia.

• Begun construction of additional greenhouses to complement KHRN's initial 80,000 sq. ft. greenhouse.

• Established distribution networks to supply high quality medical cannabis produced in KHRN's main facility, with signed agreements with 903 pharmacies across Colombia.

Conclusion: given the informal investor discussions in chat rooms and questions I received from readers asking generally about the weakness in Khiron’s stock price and specifically with respect to this article, I have to believe it played some role in the KHRN market action last week. I believe the points made above should convince anyone that KHRN is the cannabis leader in Latin America. I believe the stock will snap back relatively quickly as more and more investors realize that KHRN is the leader in Latin America and deserves to trade at a much higher market cap.